Epidiolex

The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH). The transaction, previously announced in February, was recently approved by GW Pharmaceuticals shareholders. The Jazz-GW...

Neptune Revenue Declines 63% YoY, Shifts To CPG And Branded Products Global health and wellness company Neptune Wellness Solutions Inc. (NASDAQ: NEPT) (TSX: NEPT) revealed Monday its third-quarter financial results, on the heels of announcing the purchase of a 50.1% stake in baby food and...

Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) filed an federal lawsuit last week against Britain’s GW Pharma (NASDAQ: GWPH). In the lawsuit filed in the U.S. District Court for the Western District of Texas, Canopy accuses GW Pharma of unauthorized usage of Canopy’s...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Monday that the results of the company’s positive Phase 3 clinical trial of Epidiolex oral solution in seizures related to tuberous sclerosis complex were published in JAMA Neurology.   Epidiolex is the first FDA-authorized CBD medicine for...

Benzinga's PreMarket Prep airs every morning from 8-9 a.m. ET. During that fast-paced, highly informative hour, traders and investors tune in to get the major news of the day, the catalysts behind those moves and the corresponding price action for the upcoming session. On any given...

Biopharmaceutical company GW Pharmaceuticals plc (NASDAQ: GWPH) revealed Tuesday that its revenue for the third quarter hit $137.1 million, up by 51% year-over-year. For the first nine months of this fiscal year, total revenue amounted to $378.6 million versus $202.3 million for the...

GW Pharmaceuticals plc (NASDAQ: GWPH) confirmed Monday it has obtained a notice from the Drug Enforcement Administration certifying that its Epidiolex oral solution has been descheduled and is no longer a controlled substance. “This notification from DEA fully establishes that EPIDIOLEX...

A drug from GW Pharmaceuticals plc (NASDAQ: GWPH) targeting a cause of genetic epilepsy has received Priority Review status from the U.S. Food and Drug Administration.  The Cambridge, U.K.-based company and its subsidiary Greenwich Biosciences Inc. confirmed Tuesday...

GW Pharmaceuticals plc (NASDAQ: GWPH) said Friday it has submitted a Type II Variation Application to the European Medicines Agency, applying for authorization of its Epidyolex — Epidiolex in the U.S. — cannabidiol oral solution for the management of seizures related to tuberous...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) shares are retreating following the release of fourth-quarter results. GW Pharmaceuticals reported quarterly losses of 7 cents per share, which beat the consensus estimate by 68 cents . This is a 65% increase over losses of 20 cents per share from the same...

More than 130 people a day lose their lives from opioid-connected drug overdose, according to the Health Resources and Services Administration. Because of these and similar devastating statistics that clearly depict the real status of the opioid epidemic in the country, more and more researchers...

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH), which derives a lion's share of its revenues from its cannabinoid seizure drug Epidiolex, provides value for investors due to the potential for the drug to have wide utility over both orphan and non-orphan indications, according to BofA Securities....

GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH) exceeded fourth-quarter estimates for Epidiolex sales, notching $108 million in revenue for the CBD drug, according to the company's preliminary figures.  The earnings preview triggered a brief run in the stock this week — one bulls...

GW Pharmaceuticals plc (NASDAQ: GWPH) issued preliminary unaudited fourth-quarter financial results Sunday that show total net product sales of around $108 million. The company posted preliminary net sales of $309 million for the full year ended Dec. 3. Net Epidiolex sales were projected...

A research team at Garrahan Children’s Hospital, a public pediatric research hospital in Buenos Aires, Argentina, completed the continent’s first clinical trials on CBD. The study adds overwhelming evidence of the compound’s efficacy in treating refractory epilepsy in children....